Law360 (December 22, 2003, 12:00 AM EST) -- The Supreme Court of the Netherlands sustained a cancer-therapy patent held by Immunomedics, but asked the European Court of Justice to rule on whether the Brussels Convention should be interpreted to permit cross-border enforcement of European patents where a related group of companies sells the same product in countries where that same patent has been validated.
The court held that Immunomedics' Dutch patent for highly specific monoclonal antibodies against the cancer marker, carcinoembryonic antigen, was valid. The German Patent Court also had held earlier that the...
Dutch Supreme Court Sustains Immunomedics Patent
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
